<DOC>
	<DOCNO>NCT01170637</DOCNO>
	<brief_summary>The objective current study demonstrate bioequivalence fix dose combination tablet contain ibuprofen 200 mg pseudoephedrine-HCl 30 mg ( Test ) RhinAdvilÂ® ( Reference ) fix dose combination tablet contain ibuprofen 200 mg pseudoephedrine-HCl 30 mg follow orally administration .</brief_summary>
	<brief_title>Bioequivalence Fixed Dose Combination Tablet Containing 200 mg Ibuprofen 30 mg Pseudoephedrine-HCl Compared RhinAdvil ( R ) ( 200 mg Ibuprofen 30 mg Pseudoephedrine-HCl ) Fixed Dose Combination Tablet Administered Healthy Volunteers .</brief_title>
	<detailed_description />
	<mesh_term>Pseudoephedrine</mesh_term>
	<mesh_term>Ephedrine</mesh_term>
	<mesh_term>Ibuprofen</mesh_term>
	<criteria>Inclusion criterion 1 . Healthy male female accord follow criterion : Based upon complete medical history , include physical examination , vital sign ( Blood pressure ( BP ) , Pulse rate ( PR ) ) , 12lead electrocardiogram ( ECG ) , clinical laboratory test 2 . Age 21 50 year 3 . BMI 18.5 29.9 kg/m2 4 . Signed date write informed consent prior admission study accordance Good Clinical Practice ( GCP ) local legislation Exclusion criteria 1 . Any finding medical examination ( include BP , PR ECG ) deviate normal clinical relevance 2 . Any evidence clinically relevant concomitant disease 3 . Any relevant Gastrointestinal ( e.g . ulcera , hernia , bleeding spasm ) , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder 4 . Any relevant surgery gastrointestinal tract ( except appendectomy ) 5 . Diseases central nervous system ( epilepsy ) psychiatric disorder neurological disorder 6 . History relevant orthostatic hypotension , faint spell blackouts 7 . Chronic relevant acute infection 8 . History relevant allergy hypersensitivity ( include allergy drug excipients ) judge clinically relevant investigator 9 . Intake drug long halflife ( &gt; 24 hour ) within least 1 month less 10 halflives respective drug prior first drug administration 10 . Use drug might reasonably influence result trial base knowledge time protocol preparation within 10 day prior randomisation 11 . Participation another trial investigational drug within 2 month prior administration trial 12 . Smoker ( &gt; 10 cigarette &gt; 3 cigar &gt; 3 pipes/day ) 13 . Inability refrain smoke trial day judge investigator 14 . Alcohol abuse ( average consumption 20 g/day female 30 g/day male ) 15 . Drug abuse 16 . Blood donation ( 100 mL within four week prior administration trial drug study ) 17 . Excessive physical activity within 1 week prior randomisation trial 18 . Any laboratory value outside reference range clinical relevance 19 . Inability comply dietary regimen study centre 20 . Unwilling avoid excessive sunlight exposure 21 . Use drug might reasonably influence result trial prolong QT/QTc interval within 10 day prior administration trial , CYP2C8 substrates amiodarone , amodiaquine , paclitaxel , rosiglitazone , pioglitazone repaglinide CYP2C9 warfarin , tolbutamide , phenytoin , losartan , acenocoumarol within 1 month six half life ( whichever great ) 22 . A marked baseline prolongation QTc interval ( e.g. , repeated demonstration QTc interval &gt; 450 m ) 23 . A history additional risk factor torsade de pointes ( e.g. , heart failure , hypokalaemia , family history Long QT Syndrome )</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>May 2012</verification_date>
</DOC>